Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- Tomer Izraeli
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Beta
- -1.34
- Country
- IL
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- 13.23
Financials
Net Income
$-1.42MEBITDA
$-4.17MFree Cash Flow
$-1.96MEPS (diluted)
$-0.79Shares Outstanding (diluted)
1.81M-56.9%Operating Expenses
$4.17MCash & Debt
$15.05MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-3.33M | $-2.07 |
| 2024 | $0.00 | $-1.54M | $-134.14 |
| 2023 | $0.00 | $-600.0K | $0.00 |
| 2022 | $0.00 | $-779.0K | $0.00 |
| 2021 | $0.00 | $-711.0K | $0.00 |
| 2020 | $0.00 | $-73.0K | $0.00 |
Valuation
PLRZhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-40.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·1d ago·Negative
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform A new patent application covers Polyrizon's proprietary mucoadhesive platform and its potential applications in nasal drug delivery.
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker First patient marks Polyrizon's transition into a clinical-stage company. The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker in patients with seasonal allergic rhinitis Raanana, Israel, Sept.
View source ↗ - Newsglobenewswire.com·31d ago·Negative
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement RAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd.
View source ↗ - Newsglobenewswire.com·33d ago·Negative
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement RAANANA, ISRAEL, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direct offering. In a…
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study Raanana, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX™ Allergy Blocker (PL-14).
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
…five U.S. clinical sites and advances its NASARIX™ study toward enrollment of 120 patients Raanana, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX™ Allergy Blocker (PL-14).
View source ↗
Insider trading
Open-market buys and sells by PLRZ officers and directors.
- Bought
- —
- Sold
- $133k
0 trades
6 trades
- Izraeli Tomersold
- Carmel Lironsold
- Adler Ozsold
- Carmel Lironsold
- Izraeli Tomersold
- Turgeman Tidharsold
19 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PLRZ.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.